TSHR CRE-Luc HEK293
CBP71485
I. Background | |
G 蛋白偶聯(lián)受體(GPCR)是跨膜蛋白受體,其特征是配體數(shù)量可變,包括內(nèi)源性神 經(jīng)遞質(zhì)和激素,也包括外源性天然和人工化合物。激動劑與受體結(jié)合后會觸發(fā)信號通路的 激活;而拮抗劑則會阻礙激動劑介導(dǎo)的受體激活。反向激動劑除像拮抗劑一樣干擾激動劑 外,還會抑制受體的組成活性。 |
|
II. Description | |
TSHR CRE-Luc HEK293 報(bào)告基因藥靶模型很好的模擬了體內(nèi) TSHR 的信號轉(zhuǎn)導(dǎo)過程,原理見下圖所示。 |
|
Figure 1. TSHR CRE-Luc HEK293細(xì)胞模型原理圖
|
|
III. Introduction | |
Expressed gene: | TSHR |
Stability: | 32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
Freeze Medium: | 90% FBS+10% DMSO |
Culture Medium: | DMEM+10%FBS+2 μg/ml puromycin+200 μg/ml hygromycin |
Mycoplasma Testing: | Negative |
Storage: | Liquid nitrogen |
Application(s): | Functional assay for TSHR |
Transducer: | Gs |
IV. Representative Data Figure 2. Recombinant TSHR CRE-Luc HEK293 stably expressing TSHR. Figure 3. Dose Response of Agonists in TSHR CRE-Luc HEK293(C31). |
|